The FDA approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer.
Read more: FDA Approves Drug to Reduce Bone Marrow Suppression Caused by Chemotherapy